discontinued marketing of the products subject to those NDAs and ANDAs. Additional ANDAs that refer to these products may also be approved by the Agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Dated: October 26, 2015.

# Leslie Kux,

Associate Commissioner for Policy. [FR Doc. 2015–27740 Filed 10–29–15; 8:45 am] BILLING CODE 4164–01–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket No. FDA-2014-N-1794]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Impact of Ad Exposure Frequency on Perception and Mental Processing of Risks and Benefit Information in Direct-to-Consumer Prescription Drug Ads

**AGENCY:** Food and Drug Administration, HHS.

#### ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Impact of Ad Exposure Frequency on Perception and Mental Processing of Risks and Benefit Information in Directto-Consumer Prescription Drug Ads" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. **FOR FURTHER INFORMATION CONTACT:** FDA

PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE–14526, Silver Spring, MD 20993–0002, *PRAStaff*@ *fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** On June 29, 2015, the Agency submitted a proposed collection of information entitled "Impact of Ad Exposure Frequency on Perception and Mental Processing of Risks and Benefit Information in Direct-to-Consumer Prescription Drug Ads" to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and

has assigned OMB control number 0910–0803. The approval expires on September 30, 2018. A copy of the supporting statement for this information collection is available on the Internet at *http://www.reginfo.gov/ public/do/PRAMain.* 

Dated: October 26, 2015.

# Leslie Kux,

Associate Commissioner for Policy. [FR Doc. 2015–27743 Filed 10–29–15; 8:45 am] BILLING CODE 4164–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket No. FDA-2014-N-1491]

### Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Survey of Pharmacists and Patients; Variations in the Physical Characteristics of Generic Drug Pills and Patient Perceptions

**AGENCY:** Food and Drug Administration, HHS.

# ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Survey of Pharmacists and Patients; Variations in the Physical Characteristics of Generic Drug Pills and Patient Perceptions" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE–14526, Silver Spring, MD 20993–0002, *PRAStaff@ fda.hhs.gov.* 

SUPPLEMENTARY INFORMATION: On May 28, 2015, the Agency submitted a proposed collection of information entitled "Survey of Pharmacists and Patients: Variations in the Physical Characteristics of Generic Drug Pills and Patient Perceptions" to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0801. The approval expires on September 30, 2018. A copy of the supporting statement for this information collection is available on the Internet at http:// www.reginfo.gov/public/do/PRAMain.

Dated: October 26, 2015. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2015–27742 Filed 10–29–15; 8:45 am] BILLING CODE 4164–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

# **Performance Review Board Members**

Title 5, U.S.C. Section 4314(c)(4) of the Civil Service Reform Act of 1978, Public Law 95–454, requires that the appointment of Performance Review Board Members be published in the **Federal Register**.

The following persons may be named to serve on the Performance Review Boards or Panels, which oversee the evaluation of performance appraisals of Senior Executive Service members of the Department of Health and Human Services.

Employee last name	Employee first name
Agrawal	Shantanu
Atkinson	Leslie
Boulanger	Jennifer
Bowers	Tonya
Burton	Adriane
Cannistra	Jennifer
Cantwell	Kathleen
Carter	Cathy
Cavanaugh	Sean
Cheatham	Tina
Cheever	Laura
Conway	Patrick
Counihan	Keven
Dammons	Cheryl
Devoss	Elizabeth
Espinosa	Diana
Etziner	Michael
Garcia	Alexandra
Garner	Jacqueline
Goldhaber	Ben
Goodman	Richard
Hamilton	Thomas
Hammarlund	John
Handley	Elisabeth
Hartstein	Marc
Haseltine	Amy
Hattery	Debbra
Heffler	Stephen
Hill	Timothy
Jackson	Karen
Kane	Daniel
Kavanagh	Laura
Kerr	James
Killoran	Beth
Kramer	Martin
Kretschmaier	Michon
Lewis	Lisa
Lodes	Lori
Lu	Michael
Macrae	James
Malcomson	Dennis
Mills	George
Montilla	Maria
Moody-Williams	Jean
Morris	Thomas
Murray	Renard